Latest Breaking News On - கிலியட் வாழ்க்கை அறிவியல் - Page 1 : comparemela.com

Centre places export of Remdesivir, API in restricted category

Centre places export of Remdesivir, API in restricted category
businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.

Zydus cadilaDr reddy labsGilead life sciencesLife sciencesHetero drugsJubilant ingreviaஜய்துச் காடிலாடாக்டர் சிவப்பு ஆய்வகங்கள்கிலியட் வாழ்க்கை அறிவியல்வாழ்க்கை அறிவியல்ஹெடரொ மருந்துகள்

Remdesivir output jumps 10 times, govt halts central allocation to states

Remdesivir output jumps 10 times, govt halts central allocation to states By IANS | 0 Views Remdesivir output jumps 10 times, govt halts central allocation to states. Image Source: IANS News New Delhi, May 29 : As the production of Remdesivir was ramped up ten times from 33,000 vials per day to 3.5 lakh, the Central government on Saturday decided to discontinue the central allocation of Remdesivir vials to states. Minister of State for Chemicals and Fertilisers, Mansukh Mandaviya, made the announcement and also directed the National Pharmaceuticals Pricing Agency and Central Drugs Standard Control Organisation (CDSCO) to continuously monitor the availability of Remdesivir in the country. The Minister informed that the production of Remdesivir was ramped up ten times from 33,000 vials per day on April 11 this year to 3,50,000 vials per day on Saturday.

United statesNew delhiZydus cadilaMansukh mandaviyaDr reddy labNational pharmaceuticals pricing agencyCentral drugs standard control organisationGilead life sciencesJubilant pharmaஒன்றுபட்டது மாநிலங்களில்புதியது டெல்ஹிஜய்துச் காடிலாமன்சுக் மண்டவியாடாக்டர் சிவப்பு ஆய்வகம்மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்கிலியட் வாழ்க்கை அறிவியல்

Pharma Set to Lose Millions as India Mulls Dropping Remdesivir To Treat COVID-19

Just as India s drug manufacturers and pharma businesses are catching up with demands for anti-viral drug Remdesivir, plans are afoot to remove the drug from the list.

Sun pharmaZydus cadilaRichard petoSanjith saseedharanRandeep guleriaGurpreet sandhuKiran khushal patilGanga ramReddy labCouncil for healthcareWorld health organizationIndia institute of medical sciencesGilead life sciencesSl raheja hospital department of critical careAll india instituteMedical sciences

Remdesivir production capacity ramped up to 1 19 crore vials per month: Centre

Remdesivir production capacity ramped up to 1.19 crore vials per month: Centre To augment the domestic production capacity, all the seven manufacturers of remdesivir in the country were asked to ramp up production quickly, the ministry said in a statement PTI | May 18, 2021 | Updated 13:00 IST The production capacity of remdesivir used for the treatment of COVID-19 has increased from 38 lakh vials per month to nearly 1.19 crore vials per month, the Ministry of Chemicals and Fertilizers said on Monday. Remdesivir is manufactured in India under voluntary licenses granted by Gilead Life Sciences to 7 pharmaceutical companies Cipla, Dr Reddy s, Hetero, Jubilant Pharma, Mylan, Syngene and Zydus Cadila, it added.

Beta cyclodextrinZydus cadilaMinistry of chemicalsMinistry of external affairsGilead life sciencesJubilant pharmaExternal affairsஜய்துச் காடிலாஅமைச்சகம் ஆஃப் இரசாயனங்கள்அமைச்சகம் ஆஃப் வெளிப்புறம் வாழ்க்கைத்தொழில்கள்கிலியட் வாழ்க்கை அறிவியல்மகிழ்ச்சி பார்மாவெளிப்புறம் வாழ்க்கைத்தொழில்கள்

Remdesivir production capacity increased to around 1 19 cr crore vials a month: Govt | Udaipur News | Udaipur Latest News

Remdesivir production capacity increased to around 1.19 cr crore vials a month: Govt New Delhi : The production capacity of remdesivir used for the treatment of COVID-19 has increased from 38 lakh vials per month to nearly 1.19 crore vials per month, the Ministry of Chemicals and Fertilizers said on Monday. Remdesivir is manufactured in India under voluntary licenses granted by Gilead Life Sciences to 7 pharmaceutical companies Cipla, Dr Reddy”s, Hetero, Jubilant Pharma, Mylan, Syngene and Zydus Cadila, it added. To augment the domestic production capacity, all the seven manufacturers of remdesivir in the country were asked to ramp up production quickly, the ministry said in a statement.

New delhiBeta cyclodextrinZydus cadilaMinistry of chemicalsMinistry of external affairsGilead life sciencesJubilant pharmaExternal affairsபுதியது டெல்ஹிஜய்துச் காடிலாஅமைச்சகம் ஆஃப் இரசாயனங்கள்அமைச்சகம் ஆஃப் வெளிப்புறம் வாழ்க்கைத்தொழில்கள்கிலியட் வாழ்க்கை அறிவியல்மகிழ்ச்சி பார்மாவெளிப்புறம் வாழ்க்கைத்தொழில்கள்தலைப்புச் செய்திகள்